Advanced search
Publication Cover
Cancer Management and Research Volume 12, 2020 - Issue
Submit an article Journal homepage
93
Views
5
CrossRef citations to date
0
Altmetric
Original Research

MicroRNA-139 Suppresses the Tumorigenicity of Triple Negative Breast Cancer Cells by Targeting SOX8

Liangliang Dong1 Department of Medical Oncology, Yantai Yuhuangding Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, People’s Republic of China
,
Dongmei Zhou2 Department of Oncology, Yantai Shan Hospital, Yantai 264000, People’s Republic of China
,
Chunxia Xin3 Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, People’s Republic of China
,
Bing Liu3 Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, People’s Republic of China
&
Ping Sun3 Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, People’s Republic of ChinaCorrespondence[email protected]
Pages 9417-9428 | Published online: 30 Sep 2020

References

  • LaBarge MA, Samson S, Miyano M. Breast cancer beyond the age of mutation. Gerontology. 2015;62(4):434–442. doi:10.1159/00044103026539838
  • Pogoda K, Niwinska A, Murawska M, Pienkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1):388. doi:10.1007/s12032-012-0388-423292831
  • Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235–244. doi:10.1016/S1470-2045(07)70074-817329194
  • Pajic M, Froio D, Daly S, et al. miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Res. 2018;78(2):501–515. doi:10.1158/0008-5472.CAN-16-310529180477
  • Liu D, Huo X, Gao L, Zhang J, Ni H, Cao L. NF-kappaB and Nrf2 pathways contribute to the protective effect of Licochalcone A on dextran sulphate sodium-induced ulcerative colitis in mice. Biomed Pharmacother. 2018;102:922–929. doi:10.1016/j.biopha.2018.03.13029710547
  • Joerger M, Thurlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther. 2013;13:165–178. doi:10.1586/era.12.17223406558
  • Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281. doi:10.1016/S0092-8674(04)00045-514744438
  • Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3(3):83–92.22468167
  • Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013;531(1):8–14. doi:10.1016/j.gene.2013.08.06223994196
  • Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol. 2010;4(3):230–241. doi:10.1016/j.molonc.2010.04.00920537965
  • Huang LL, Huang LW, Wang L, Tong BD, Ding XS. Potential role of miR-139-5p in cancer diagnosis, prognosis and therapy (Review). Oncol Lett. 2017;14(2):1215–1222. doi:10.3892/ol.2017.635128789336
  • Miyoshi J, Toden S, Yoshida K, et al. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep. 2017;7:43393. doi:10.1038/srep4339328262692
  • Watanabe K, Amano Y, Ishikawa R, et al. Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer. Cancer Med. 2015;4(10):1573–1582. doi:10.1002/cam4.50526256448
  • Yan G, Li Y, Zhan L, et al. Decreased miR-124-3p promoted breast cancer proliferation and metastasis by targeting MGAT5. Am J Cancer Res. 2019;9(3):585–596.30949412
  • Feng X, Luo Q, Wang H, Zhang H, Chen F. MicroRNA-22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3. J Cell Physiol. 2018;233(9):6705–6713. doi:10.1002/jcp.26331
  • Dai H, Gallagher D, Schmitt S, et al. Role of miR-139 as a surrogate marker for tumor aggression in breast cancer. Hum Pathol. 2017;61:68–77. doi:10.1016/j.humpath.2016.11.00127864119
  • Hua W, Sa KD, Zhang X, et al. MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha. Biochem Biophys Res Commun. 2015;463(4):1077–1083. doi:10.1016/j.bbrc.2015.06.06126079880
  • Gu SQ, Luo JH, Yao WX. The regulation of miR-139-5p on the biological characteristics of breast cancer cells by targeting COL11A1. Math Biosci Eng. 2019;17(2):1428–1441. doi:10.3934/mbe.202007332233587
  • Tang H, Chen B, Liu P, et al. SOX8 acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Carcinogenesis. 2019;40(10):1278–1287. doi:10.1093/carcin/bgz03430810729
  • Chen B, Tang H, Chen X, et al. Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Cancer Manag Res. 2018;11:179–190. doi:10.2147/CMAR.S18715130613165
  • Xie SL, Fan S, Zhang SY, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. Int J Cancer. 2018;142(6):1252–1265. doi:10.1002/ijc.3113429071717
  • Chen S, Li H, Li X, et al. High SOX8 expression promotes tumor growth and predicts poor prognosis through GOLPH3 signaling in tongue squamous cell carcinoma. Cancer Med. 2020;9(12):4274–4289. doi:10.1002/cam4.304132307911
  • Rask L, Balslev E, Søkilde R, et al. Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cell Oncol (Dordr). 2014;37(3):215–227. doi:10.1007/s13402-014-0176-625027758

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.